Mass Tort Litigation in the U.S.: Structure, Examples, and Key Differences from Class Actions

Mass tort litigation represents one of the most procedurally complex areas of American civil law, consolidating thousands of individual injury claims arising from a single product, substance, or event into coordinated judicial proceedings. This page covers the structural mechanics of mass torts, how they differ from class actions, the regulatory and procedural frameworks that govern them, and the classification boundaries that determine which litigation pathway applies. Understanding these distinctions matters because the choice of procedure directly shapes how plaintiffs recover, how defendants manage liability, and how federal courts allocate judicial resources.

• Definition and Scope
• Core Mechanics or Structure
• Causal Relationships or Drivers
• Classification Boundaries
• Tradeoffs and Tensions
• Common Misconceptions
• Checklist or Steps (Non-Advisory)
• Reference Table or Matrix

Definition and Scope

A mass tort is a civil wrong — grounded in tort law in the U.S. — in which a single defendant or group of defendants causes injuries to a large number of plaintiffs through a common product, conduct, or event. Unlike a single-plaintiff personal injury case, mass torts aggregate claims that share a common factual nucleus while preserving each plaintiff's individual legal identity and right to a distinct damage award.

The scope of mass tort litigation in the U.S. federal system is governed primarily by 28 U.S.C. § 1407, which authorizes the Judicial Panel on Multidistrict Litigation (JPML) to transfer and consolidate civil actions involving one or more common questions of fact to a single federal district for pretrial proceedings. The JPML, established by Congress in 1968, has transferred over 1,000 MDL dockets since its creation, and as of the most recent annual report published by the Administrative Office of the U.S. Courts, MDL cases have at times represented more than 50 percent of the entire federal civil caseload (Administrative Office of the U.S. Courts, Federal Judicial Caseload Statistics).

Mass torts commonly arise in four categories:

• Pharmaceutical and medical device litigation (e.g., opioid manufacturer cases, pelvic mesh implants)
• Toxic tort / environmental exposure (e.g., asbestos, PFAS contamination, Camp Lejeune water contamination)
• Consumer product defects (e.g., defective airbags, talcum powder)
• Disaster and industrial accident (e.g., oil spills, industrial explosions)

Core Mechanics or Structure

Mass tort litigation operates through two primary procedural vehicles: Multidistrict Litigation (MDL) in federal court and coordinated proceedings in state courts (sometimes called "multicounty litigation" or MCL).

Federal MDL Procedure

Under multidistrict litigation MDL explained, once the JPML centralizes cases before a transferee judge, the proceeding moves through recognizable phases:

1. Bellwether selection — The transferee judge, often with input from a Plaintiffs' Steering Committee (PSC) and Defense Liaison Counsel, selects a small number of representative cases for full trial or trial-ready preparation. Bellwether results signal settlement ranges for the broader docket.
2. General causation discovery — Plaintiffs establish that the defendant's product or conduct can cause the alleged type of harm in any person (population-level causation), distinct from specific causation for individual plaintiffs.
3. Expert vetting under Daubert — Because mass torts turn heavily on epidemiological and scientific evidence, courts conduct extensive Daubert standard expert testimony hearings before allowing experts to testify. The Supreme Court's Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), controls admissibility of scientific expert testimony in federal courts.
4. Global settlement negotiation — The majority of MDLs resolve through aggregate settlements rather than individual trials. Defendants negotiate a settlement fund; claims administrators then apply point systems or grid formulas to distribute awards based on injury severity, duration of use, and other plaintiff-specific factors.
5. Remand or dismissal — Cases not resolved in the MDL are remanded to their originating districts for individual trial under 28 U.S.C. § 1407(a).

State Court Coordination

Many mass tort plaintiffs file in state court to avoid federal jurisdiction or because state product liability law overview or comparative fault rules by state are more favorable. States including New Jersey, California, and Delaware have established formal complex litigation programs that mirror MDL consolidation.

Causal Relationships or Drivers

Three structural forces drive mass tort formation:

1. Epidemiological evidence of population-level harm. Mass torts require plaintiffs to demonstrate, through published research-based studies, that exposure to a substance or product elevates disease risk across a population. Without general causation, individual specific causation claims cannot survive motions to dismiss or summary judgment. The burden of proof civil cases standard (preponderance of the evidence) applies, but courts apply heightened scrutiny to expert methodology.

2. Common product or conduct with widespread distribution. Liability concentrates when a single defendant manufactured or distributed the causative product at scale — pharmaceutical drugs approved by the Food and Drug Administration (FDA) under 21 U.S.C. § 301 et seq. (Federal Food, Drug, and Cosmetic Act), asbestos-containing building materials regulated post-1971 under the Occupational Safety and Health Administration (OSHA) standards at 29 C.F.R. § 1910.1001, or chemicals subject to EPA reporting under CERCLA (42 U.S.C. § 9601 et seq.).

3. Statute of limitations timing. Because latent diseases (mesothelioma, certain cancers) may not manifest for 20 to 40 years post-exposure, mass tort dockets grow as plaintiffs discover injuries. Statute of limitations by state rules govern when claims expire; most states apply a "discovery rule" tolling limitations until the plaintiff knew or reasonably should have known of the injury and its cause.

Classification Boundaries

The boundary between a mass tort and a class action is procedurally significant and frequently misunderstood. Both aggregate claims, but the mechanisms diverge in ways that affect individual recovery and due process rights.

Rule 23 Class Actions are governed by Federal Rule of Civil Procedure 23, which requires: (a) numerosity, (b) commonality, (c) typicality, and (d) adequacy of representation. For a damages class under Rule 23(b)(3), plaintiffs must demonstrate that common questions predominate over individual ones. Personal injury mass torts almost never satisfy the predominance requirement because individual damages — specific causation, injury severity, medical history, lost wages — are highly individualized. The Supreme Court confirmed this in Amchem Products, Inc. v. Windsor, 521 U.S. 591 (1997), holding that asbestos personal injury claims could not be certified as a class under Rule 23(b)(3).

Mass Torts preserve individual plaintiff autonomy. Each plaintiff retains the right to opt into or out of settlements, pursue individual trials, and assert unique damage theories. Compensatory damages explained and punitive damages in U.S. courts are assessed plaintiff-by-plaintiff, not as an aggregate class award distributed pro rata.

A hybrid exists: the settlement class action, where courts certify a class solely for purposes of approving a negotiated global settlement. Amchem and Ortiz v. Fibreboard Corp., 527 U.S. 815 (1999), both involved and ultimately restricted this mechanism.

Tradeoffs and Tensions

Efficiency versus individual justice. MDL consolidation reduces duplicative discovery and lowers costs for courts and parties. However, critics — including the 2019 report of the American Law Institute's Aggregate Litigation project — note that bellwether trial results do not always translate fairly to outlier plaintiffs with atypical injuries.

Settlement pressure dynamics. When a defendant negotiates a global settlement fund, plaintiffs who reject the settlement face the prospect of individual trials with diminished resources. Courts have grappled with whether this creates coercive pressure that undermines the voluntariness required by due process.

Litigation financing influence. Third-party litigation funding, largely unregulated at the federal level, has expanded mass tort dockets by financing plaintiff law firm infrastructure. The Government Accountability Office (GAO) examined litigation funding in a 2023 report, noting disclosure practices remain inconsistent across federal districts (GAO-23-105491).

Damage caps by state creating forum disparities. Because state tort reform laws impose caps on non-economic or punitive damages at varying levels, defendants and plaintiffs engage in forum selection battles that distort where mass tort claims concentrate.

Common Misconceptions

Misconception 1: Mass tort plaintiffs automatically receive the same award.
Each plaintiff's recovery is individually calculated. Settlement grid formulas assign values based on injury tier, product exposure duration, and individual medical history. Two plaintiffs in the same MDL with different diagnoses receive different amounts.

Misconception 2: Filing in an MDL means a plaintiff's case will go to trial.
Historically, fewer than 3 percent of MDL cases are resolved by trial. The U.S. Chamber Institute for Legal Reform and academic studies of JPML data confirm that the overwhelming majority of MDL cases resolve through settlement, voluntary dismissal, or transfer back to originating courts without trial.

Misconception 3: A mass tort and a class action are the same proceeding.
As established in Amchem (1997), they are distinct. A class action extinguishes unnamed class members' individual claims upon certification; a mass tort plaintiff retains an individual claim even when cases are coordinated for pretrial purposes.

Misconception 4: MDL consolidation always occurs in federal court.
State mass tort coordination exists independently of the federal JPML. New Jersey's MCL program in Middlesex County and California's complex litigation courts handle large state-court mass tort inventories entirely outside federal jurisdiction.

Misconception 5: Strict liability in U.S. law always applies in mass tort product cases.
Applicable liability theory depends on state law and the nature of the claim. Pharmaceutical cases are frequently governed by a failure-to-warn negligence theory rather than strict products liability, particularly after Wyeth v. Levine, 555 U.S. 555 (2009), which addressed federal preemption of state failure-to-warn claims against drug manufacturers.

Checklist or Steps (Non-Advisory)

The following sequence describes the standard procedural phases of a federal mass tort MDL proceeding, derived from JPML rules and published transferee court case management orders:

Phase 1 — JPML Transfer Petition
- [ ] Movant files petition with JPML identifying common factual questions across pending federal cases
- [ ] JPML issues hearing order; parties submit briefs and respond at scheduled hearing session
- [ ] JPML issues transfer order or denies consolidation; identifies transferee district and judge

Phase 2 — MDL Organization
- [ ] Transferee judge issues initial case management order
- [ ] Court establishes Plaintiffs' Steering Committee (PSC) and Defense Liaison Counsel
- [ ] Master complaint filed; defendants file master answer or motions to dismiss

Phase 3 — Discovery
- [ ] General causation discovery process civil injury cases commences (document production, depositions in personal injury cases)
- [ ] Expert witnesses injury litigation designated; Daubert motions briefed and argued
- [ ] Fact sheets (plaintiff profile forms) completed for individual plaintiffs

Phase 4 — Bellwether Proceedings
- [ ] Bellwether pool selected through negotiated or court-ordered process
- [ ] Individual discovery completed on bellwether plaintiffs
- [ ] Bellwether trials conducted or cases settled on eve of trial

Phase 5 — Global Resolution
- [ ] Settlement fund negotiated; claims administrator appointed
- [ ] Individual plaintiffs review and accept or reject settlement offers
- [ ] Lien resolution completed (lien resolution in injury cases); Medicare Medicaid liens injury law compliance verified
- [ ] Non-settling cases remanded to originating districts under 28 U.S.C. § 1407(a)

Reference Table or Matrix

Mass Tort vs. Class Action: Key Structural Comparisons

Selected Major U.S. Mass Tort MDLs by Category

References

• Judicial Panel on Multidistrict Litigation — JPML
• 28 U.S.C. § 1407 — Multidistrict Litigation (via Cornell LII)
• Federal Rule of Civil Procedure 23 — Class Actions (via Cornell LII)
• Administrative Office of the U.S. Courts — Federal Judicial Caseload Statistics
• [GAO Report GAO-23-105491: Litigation